Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Can Biologics Make You Rich?
Motley Fool
Sunday, January 27, 2013 - 11:21am
tags:
AbbVie, Amgen, Biogen Idec, JNJ, Roche
This Week in Biotech: Part 2
Motley Fool
Sunday, January 27, 2013 - 11:20am
tags:
Roche, Novartis, Impax Laboratories, MAP Pharmaceuticals, Allergan
Bristol-Myers Squibb Company Earnings Call Insights: Tax Rate Drop and PD-1 Readout
Wall Street Cheat Street
Sunday, January 27, 2013 - 11:19am
tags:
Bristol-Myers Squibb, earnings
Which Biotech Company Will Be Bought Out Next?
Motley Fool
Sunday, January 27, 2013 - 11:18am
tags:
Theravance, GSK, Astellas, Vivus, Eli Lilly, Immunogen, Roche, M&A
Celgene 2017 Guidance: 2 Times 2013 Revenue
Seeking Alpha
Sunday, January 27, 2013 - 11:15am
tags:
Celgene
China Biotech In Review: 2012 China Life Science VC, M&A, And Partnering Climb
Seeking Alpha
Sunday, January 27, 2013 - 11:11am
tags:
Zhejiang Hisun Pharma, Simcere, Chongqing Huapont Pharma, Xceleron
Bristol-Myers Squibb and 3 Top Pharma Stocks with Earnings Investors Must See
Wall Street Cheat Street
Sunday, January 27, 2013 - 11:09am
tags:
Bristol-Myers Squibb, earnings, Amgen, Celgene Corporation, AmerisourceBergen
This Week in Biotech: Part 1
Motley Fool
Sunday, January 27, 2013 - 11:07am
tags:
Cellgene, Eli Lilly, Biogen Idec, Vanda, Celsion
Earnings Season: It's All About Expectations
Motley Fool
Saturday, January 26, 2013 - 11:59am
tags:
Bristol-Myers Squibb, AstraZeneca
Johnson & Johnson: Valuation, Growth Prospects, And Dividend Growth All Point To A Further Upside
Seeking Alpha
Saturday, January 26, 2013 - 11:58am
tags:
JNJ, earnings
Breaking Down Health Care's Biggest Earnings Report
Motley Fool
Saturday, January 26, 2013 - 11:57am
tags:
JNJ, earnings
Johnson & Johnson: A Dividend 'King' With A Bright Future
Seeking Alpha
Saturday, January 26, 2013 - 11:56am
tags:
JNJ
What Will Drive Merck's Growth in 2013? (video)
Motley Fool
Saturday, January 26, 2013 - 11:56am
tags:
Merck
Abbott Labs -- Not AbbVie -- Is Acting Like a Spinoff
Motley Fool
Saturday, January 26, 2013 - 11:55am
tags:
Abbott Laboratories, AbbVie
J&J shops feminine products business - WSJ
Reuters
Saturday, January 26, 2013 - 11:55am
tags:
JNJ, Women's Health
Don't Worry About Immunogen's Disappointing Quarter
Motley Fool
Saturday, January 26, 2013 - 11:53am
tags:
Immunogen
Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta In Patients With Colorectal Cancer
Yahoo/PR Newswire
Saturday, January 26, 2013 - 11:52am
tags:
Amgen, Neulasta, colorectal cancer, colon cancer
Here's a Basket of Potentially Explosive Growth
Motley Fool
Saturday, January 26, 2013 - 11:51am
tags:
Market Vectors Biotech ETF
BGI-Shenzhen Extends Tender Offer For Complete Genomics, Inc.
Yahoo/PR Newswire
Saturday, January 26, 2013 - 11:50am
tags:
BGI-Shenzhen, Complete Genomics
3 Horrendous Health-Care Stocks This Week
Motley Fool
Saturday, January 26, 2013 - 11:48am
tags:
Pacific Biosciences, Arena Pharmaceuticals, Synergy Pharmaceuticals

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.